Merck & Co., Inc. beat EPS estimates 94% of the time across 17 reported quarters (16 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| 2026-10-29 | — | — | — | Miss |
| Q22026 FY2026 | $2.10 | — | — | Miss |
| Q1 FY2026 | $-1.47 | $-1.28 | +12.9% | Beat |
| Q1 FY2026 | — | — | — | Miss |
| 2026-02-03 | $2.01 | $2.04 | +1.5% | Beat |
| Q3 FY2025 | $2.36 | $2.58 | +9.3% | Beat |
| Q2 FY2025 | $2.03 | $2.13 | +4.9% | Beat |
| Q1 FY2025 | $2.13 | $2.22 | +4.2% | Beat |
| 2025-02-04 | $1.85 | $1.72 | -7.0% | Miss |
| Q3 FY2024 | $1.50 | $1.57 | +4.7% | Beat |
| Q2 FY2024 | $2.15 | $2.28 | +6.0% | Beat |
| Q1 FY2024 | $1.88 | $2.07 | +10.1% | Beat |
Back to MRK overview · MRK holders · MRK KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.